Researchers have discovered that mRNA-based COVID-19 vaccines have a persistent effect on the innate immune system. These mechanisms may help the human body to better protect itself against ...

They found that mRNA-based COVID-19-vaccinations cause a significant and persistent change through acetylation, i.e., the binding of a chemical group to specific, immunologically relevant genes of ...

The vaccine — using messenger RNA (mRNA) technology similar to that found in some Covid vaccines — activated tumour-targeting immune cells that persisted for nearly four years after surgery in ...

uses a powerful monitoring system to reveal how the human immune system is responsive to a litany of tick triggers — some of which might be leveraged to create a protective mRNA vaccine.

Key suits were filed by third party mRNA and lipid pioneers that, while not having any mRNA-based products on the market themselves, leveraged their patent portfolios claiming a share of the ...

CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to ...

Follow-up studies confirmed that this nucleoside modification improved mRNA translation capabilities and stability. In the last decade, a series of studies highlighted the powerful potential of ...

CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing.

MRNA, NVAX Price Action: At the time of publication, Moderna shares were down 5.70% at $31.91 and Novavax shares were down 3.37% at $7.30, according to Benzinga Pro.